Board Comments on the fine levied by the Exchanges (BSE and NSE)
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 19.8 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NSE and BSE each levied a fine of Rs. 1,53,400 (including 18% GST) on Nectar Lifesciences for delaying the submission of its financial results for the quarter and year ended March 31, 2025, under Regulation 33 of SEBI's Listing Rules. The delay was 26 days at a penalty rate of Rs. 5,000 per day. The company has already paid the fine to both exchanges. The Board, at its meeting on July 7, 2025, noted the fine and decided to request a personal hearing before the exchanges' review committee to seek a waiver. The Board also directed management to ensure timely compliance with listing rules going forward.
The fine amount is small and has already been paid, so the direct financial hit is limited. However, this is a compliance lapse that investors should watch — if the company defaults again, exchanges can freeze promoter shareholdings and shift the stock to the Z category (trade-for-trade), which would hurt liquidity and sentiment.